Adipose Tissue Derived Mesenchymal Stromal/Stem Cells is under clinical development by Cell2Cure and currently in Phase II for Keratoconjunctivitis Sicca (Dry Eye). According to GlobalData, Phase II drugs for Keratoconjunctivitis Sicca (Dry Eye) have a 56% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Adipose Tissue Derived Mesenchymal Stromal/Stem Cells’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Adipose Tissue Derived Mesenchymal Stromal/Stem Cells overview

Cell therapy is under development for the treatment of corneal transplant, diabetic foot ulcer, dry eye disease, lung transplant rejection, Sjogren’s syndrome and Xerostomia. The therapeutic candidate comprises of adipose tissue derived mesenchymal stromal or stem cells. It is administered through subcutaneous route.

Cell2Cure overview

Cell2Cure is a biotherapeutic company developing ‘off-the-shelf’ adipose tissue derived mesenchymal stromal cell (ASC) products applied in a wide range of advanced-stage diseases with involvement of inflammation and immunological activity, blood circulatory disturbance, fibrosis and scar development. Cell2Cure is headquartered in Birkerod, Denmark.

For a complete picture of Adipose Tissue Derived Mesenchymal Stromal/Stem Cells’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 7 February 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.